Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca COVID-19 vaccine trial Brazil volunteer dies, trial to continue

10/21/2020 | 01:15pm EDT

(Adds Federal University of Sao Paulo statement)

SAO PAULO/FRANKFURT, Oct 21 (Reuters) - Brazilian health authority Anvisa said on Wednesday that a volunteer in a clinical trial of the COVID-19 vaccine developed by AstraZeneca and Oxford University had died but added that the trial would continue.

Oxford confirmed the plan to keep testing, saying in a statement that after careful assessment "there have been no concerns about safety of the clinical trial."

AstraZeneca declined to comment immediately.

A source familiar with the matter told Reuters the trial would have been suspended if the volunteer who died had received the COVID-19 vaccine, suggesting the person was part of the control group that was given a meningitis jab.

The Federal University of Sao Paulo, which is helping coordinate phase 3 clinical trials in Brazil, said an independent review committee had also recommended the trial continue. The university earlier confirmed the volunteer was Brazilian but gave no further personal details.

"Everything is proceeding as expected, without any record of serious vaccine-related complications involving any of the participating volunteers," the Brazilian university said in a statement.

So far, 8,000 of the planned 10,000 volunteers in the trial have been recruited and given the first dose in six cities in Brazil, and many have already received the second shot, said a university spokesman.

CNN Brasil reported that the volunteer was a 28-year-old man who lived in Rio de Janeiro and died from COVID-19 complications.

Anvisa provided no further details, citing medical confidentiality of those involved in trials.

AstraZeneca shares fell 1.8%.

Brazil's federal government has plans to purchase the UK vaccine and produce it at biomedical research center FioCruz in Rio de Janeiro, while a competing vaccine from China's Sinovac Biotech Ltd is being tested by Sao Paulo state's research center Butantan Institute.

Brazil's President Jair Bolsonaro said on Wednesday the federal government will not buy the Sinovac vaccine.

Brazil has the second deadliest outbreak of the coronavirus, after the United States, with more than 154,000 killed. It has the third largest number of cases, with more than 5.2 million infected, after the United States and India. (Reporting by Eduardo Simoes in Sao Paulo and Ludwig Burger in Frankfurt; additional reporting by Ricardo Brito and Anthony Boadle in Brasilia and Alistair Smout in London; writing by Jake Spring; editing by Jonathan Oatis and Rosalba O'Brien)

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.08% 8325 Delayed Quote.13.63%
EURO / BRAZILIAN REAL (EUR/BRL) 0.06% 5.9329 Delayed Quote.-6.70%
SINOVAC BIOTECH LTD. -0.31% 6.47 Delayed Quote.0.00%
All news about ASTRAZENECA PLC
04:46aASTRAZENECA  : Secures Conditional Chinese Approval for Lynparza in Prostate Can..
02:20aASTRAZENECA  : Merck & Co's Prostate Cancer Drug Wins Conditional Nod in China
02:05aASTRAZENECA  : Lynparza approved in China for the treatment of BRCA-mutated meta..
12:23aAstraZeneca's Lynparza Drug Approved in China for Prostate Cancer
06/23THE LATEST : Israel delays reopening of borders to tourists
06/23GENPREX  : to Move Forward With Phase 1/2 Trial of Lung Cancer Combo Therapy
06/23GLOBAL MARKETS LIVE : Microsoft, Morgan Stanley, Heineken, Twitter, AstraZeneca...
06/23STREET COLOR : Two US House Panels Seeking Details on Emergent Relationship Betw..
06/23Genprex Shares Rise 8% on FDA Review of Reqorsa Trial
06/23ASTRAZENECA  : First-in-class approval in China in this setting and first regula..
More news
Financials (USD)
Sales 2021 30 988 M - -
Net income 2021 4 559 M - -
Net Debt 2021 10 731 M - -
P/E ratio 2021 36,6x
Yield 2021 2,45%
Capitalization 153 B 153 B -
EV / Sales 2021 5,27x
EV / Sales 2022 4,55x
Nbr of Employees 76 100
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 28
Last Close Price 116,22 $
Average target price 132,57 $
Spread / Average Target 14,1%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC13.63%152 565
JOHNSON & JOHNSON3.34%428 269
ROCHE HOLDING AG10.19%321 632
PFIZER, INC.6.09%218 590
NOVARTIS AG1.55%207 926
ABBVIE INC.6.39%201 349